Sabra Health Care REIT, Inc. (SBRA) P/E Ratio History
UndervaluedTrading at 28.5x vs 5Y avg 90.8x · 40th percentile · Below historical baseline · Data 2011–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Sabra Health Care REIT, Inc. (SBRA) trades at a price-to-earnings ratio of 28.5x, with a stock price of $18.27 and trailing twelve-month earnings per share of $0.61.
The current P/E is 69% below its 5-year average of 90.8x. Over the past five years, SBRA's P/E has ranged from a low of 11.5x to a high of 765.3x, placing the current valuation at the 40th percentile of its historical range.
Compared to the Real Estate sector median P/E of 24.1x, SBRA trades at a 18% premium to its sector peers. The sector includes 174 companies with P/E ratios ranging from 0.7x to 199.8x.
Relative to the broader market, SBRA trades roughly in line with the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SBRA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SBRA Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SBRA P/E vs Peers
Senior housing and skilled nursing peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $148B | 152.1 | - | -11% | |
| $39B | 153.8 | - | +184%Best | |
| $13B | 23.2 | 0.98Best | +25% | |
| $2B | 14.5Lowest | - | +24% | |
| $9B | 23.9 | 1.11 | +96% | |
| $3B | 23.5 | - | -4% | |
| $14B | 199.8 | - | -72% | |
| $94M | 115.3 | - | -394% | |
| $500M | 226.1 | - | +134% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SBRA Historical P/E Data (2011–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $19.23 | $0.63 | 30.4x | -45% |
| FY2025 Q4 | Dec 31 2025 | $18.94 | $0.64 | 29.5x | -46% |
| FY2025 Q3 | - | $18.64 | $0.72 | 25.8x | -53% |
| FY2025 Q2 | Jun 30 2025 | $18.44 | $0.76 | 24.3x | -56% |
| FY2025 Q1 | Mar 31 2025 | $17.47 | $0.59 | 29.6x | -46% |
| FY2024 Q4 | - | $17.32 | $0.53 | 32.7x | -41% |
| FY2024 Q3 | Sep 30 2024 | $18.61 | $0.41 | 45.0x | -18% |
| FY2024 Q2 | Jun 30 2024 | $15.40 | $0.22 | 70.5x | +28% |
| FY2024 Q1 | Mar 31 2024 | $14.77 | $0.21 | 70.5x | +28% |
| FY2023 Q4 | Dec 31 2023 | $14.27 | $0.06 | 243.9x | +344% |
| FY2022 Q2 | - | $13.97 | $0.19 | 72.6x | +32% |
| FY2021 Q1 | Mar 31 2021 | $17.36 | $0.66 | 26.3x | -52% |
| FY2020 Q4 | - | $17.37 | $0.67 | 25.9x | -53% |
| FY2020 Q3 | Sep 30 2020 | $13.79 | $0.69 | 20.0x | -64% |
| FY2020 Q2 | - | $14.43 | $0.63 | 22.9x | -58% |
| FY2020 Q1 | - | $10.92 | $0.95 | 11.5x | -79% |
| FY2019 Q4 | - | $21.34 | $0.34 | 62.8x | +14% |
| FY2019 Q3 | Sep 30 2019 | $22.96 | $0.03 | 765.3x | +1293% |
| FY2019 Q2 | Jun 30 2019 | $19.69 | $0.11 | 179.0x | +226% |
| FY2019 Q1 | Mar 31 2019 | $19.47 | $0.73 | 26.7x | -51% |
| FY2018 Q4 | Dec 31 2018 | $16.48 | $1.51 | 10.9x | -80% |
| FY2018 Q3 | Sep 30 2018 | $23.12 | $2.19 | 10.6x | -81% |
| FY2018 Q2 | Jun 30 2018 | $21.73 | $2.10 | 10.3x | -81% |
| FY2018 Q1 | Mar 31 2018 | $17.65 | $1.29 | 13.7x | -75% |
| FY2017 Q4 | Dec 31 2017 | $18.77 | $1.20 | 15.6x | -72% |
| FY2017 Q3 | Sep 30 2017 | $21.94 | $0.94 | 23.3x | -58% |
| FY2017 Q2 | Jun 30 2017 | $24.10 | $1.18 | 20.4x | -63% |
| FY2017 Q1 | Mar 31 2017 | $27.93 | $1.44 | 19.4x | -65% |
| FY2016 Q4 | Dec 31 2016 | $24.42 | $0.95 | 25.7x | -53% |
| FY2016 Q3 | Sep 30 2016 | $25.18 | $0.98 | 25.7x | -53% |
| FY2016 Q2 | - | $20.64 | $0.87 | 23.7x | -57% |
| FY2016 Q1 | - | $20.09 | $0.58 | 34.6x | -37% |
| FY2015 Q4 | - | $20.23 | $1.10 | 18.4x | -67% |
| FY2015 Q3 | Sep 30 2015 | $23.18 | $1.11 | 20.9x | -62% |
| FY2015 Q2 | - | $25.74 | $1.18 | 21.8x | -60% |
| FY2015 Q1 | - | $33.15 | $1.22 | 27.2x | -51% |
| FY2014 Q4 | Dec 31 2014 | $30.37 | $0.75 | 40.5x | -26% |
| FY2014 Q3 | - | $24.32 | $0.67 | 36.3x | -34% |
| FY2014 Q2 | Jun 30 2014 | $28.71 | $0.60 | 47.9x | -13% |
| FY2014 Q1 | Mar 31 2014 | $27.89 | $0.30 | 92.3x | +68% |
| FY2013 Q4 | - | $26.14 | $0.74 | 35.2x | -36% |
| FY2013 Q3 | Sep 30 2013 | $23.01 | $0.58 | 39.5x | -28% |
| FY2013 Q2 | Jun 30 2013 | $26.11 | $0.48 | 54.1x | -1% |
| FY2013 Q1 | Mar 31 2013 | $29.01 | $0.66 | 44.0x | -20% |
| FY2012 Q4 | Dec 31 2012 | $21.72 | $0.53 | 41.0x | -25% |
| FY2012 Q3 | Sep 30 2012 | $20.01 | $0.61 | 32.8x | -40% |
| FY2012 Q2 | Jun 30 2012 | $17.11 | $0.54 | 31.7x | -42% |
| FY2012 Q1 | Mar 31 2012 | $16.44 | $0.46 | 35.7x | -35% |
| FY2011 Q4 | Dec 31 2011 | $12.09 | $0.39 | 31.0x | -44% |
| FY2011 Q3 | Sep 30 2011 | $9.54 | $0.20 | 47.6x | -13% |
Average P/E for displayed period: 54.9x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SBRA — Frequently Asked Questions
Quick answers to the most common questions about buying SBRA stock.
What is SBRA's P/E ratio?
Sabra Health Care REIT, Inc. (SBRA) trailing twelve-month P/E ratio is 28.5x, based on TTM diluted EPS of $0.61. The 5-year average P/E is 90.8x and the historical range spans 11.5x to 765.3x.
Is SBRA stock overvalued or undervalued?
SBRA trades at 28.5x P/E, below its 5-year average of 90.8x. At the 40th percentile of its historical range (11.5x–765.3x), the stock is priced at a discount to its own history.
Is SBRA stock expensive?
No, SBRA is not expensive on a historical basis. The current P/E of 28.5x is below the 5-year average of 90.8x and sits at the 40th percentile of its valuation range.
What is SBRA's historical P/E range?
Over the past 5 years, SBRA's P/E ratio has ranged from 11.5x to 765.3x, with a median of 30.4x and an average of 90.8x. The current P/E of 28.5x places the stock at the 40th percentile of this range. Full historical data spans 2011–2026.
How does SBRA's P/E compare to the S&P 500?
SBRA trades at 28.5x P/E versus the S&P 500 median of 24.3x. The 17% premium to the market typically reflects higher expected earnings growth or quality.
How does SBRA's valuation compare to Real Estate peers?
Sabra Health Care REIT, Inc. P/E of 28.5x compares to the Real Estate sector median of 24.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SBRA's PEG ratio?
SBRA PEG ratio is N/A, based on a P/E of 28.5x and EPS growth of 18.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SBRA's earnings yield?
SBRA earnings yield is 3.50%, the inverse of its 28.5x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.